Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NOR-SWITCH

- PMLiVE

Novartis gets FDA panel backing for biosimilar Enbrel

However Amgen claims patent protection for the psoriatic arthritis therapy is valid until 2029

EU flag

European pharma ‘to grow 3.2% per year by 2022’

Forecast predicts AbbVie’s Humira will be knocked off the top spot

Why health psychology should inform pharma strategy

In the March 2016 edition of PME, Ella Nuttall (Health Psychology Specialist at Lucid Group) discusses why pharma should look to health psychology and adopt a behaviour-change strategy to inform...

Lucid Group Communications Limited

- PMLiVE

Michael J Fox Foundation backs wearable device trial

Partners with chip manufacturer Intel and Cynapsus Therapeutics on Parkinson's study

12 Connected Health

Seizing the opportunities in a new era of care

Havas Lynx

- PMLiVE

Clock ticking on biosimilar Enbrel in US

10-month review for drug

Eli Lilly HQ

Lilly set to launch Lantus biosimilar in the US next year

Settlement ends the company's legal dispute with Sanofi

- PMLiVE

Amgen and Allergan close on Avastin biosimilar filing

ABP 215 matches reference drug in study

- PMLiVE

AbbVie’s Humira wins ninth US approval

FDA approves multi-blockbuster for inflammatory skin disease

National Institute for Health and Care Excellence NICE logo

NICE set to recommend seven biologics for severe rheumatoid arthritis

List includes Roche's RoActemra and biosimilars Inflectra and Remsima

- PMLiVE

First Merck/Samsung biosimilar cleared in South Korea

Approval of Brenzys further opens up competition in biosimilar market

- PMLiVE

Novartis launches first biosimilar Zarxio in the US

Follows Amgen's failure to block Neupogen-version from release

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links